Background: Plasmacytoma is an hematological malignancy that originates in bone. It may involve a single skeletal location. Notably, these lesions can progress to involve multiple segments in 50% of cases, at which point they are classified as having multiple myeloma (MM).
Case Description: One year ago, this patient had undergone a D6 laminectomy and biopsy for plasmacytoma. Now at age 73, she newly presented with the onset of a progressive paraparesis of 4 weeks' duration. On examination, she had 3/5 strength in both lower extremities accompanied by diffuse hyperreflexia, and bilateral Babinski signs. She underwent a D5-D7 decompression, D6 corpectomy with anterior mesh cage reconstruction, and a D3-D9 posterior fusion.
Conclusion: Patients originally treated for plasmacytoma present 50% of the time with the new onset of neurological symptoms and signs due to the subsequent evolution of MM. As these lesions may be refractory to radiation and/or chemotherapy, surgery is often warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326062 | PMC |
| http://dx.doi.org/10.25259/SNI_442_2021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A single giant frontoparietal intraaxial hydatid cyst in a 5-year-old female: a case report and review of literature.
Oxf Med Case Reports
January 2025
Neurosurgery Department, Al-Ahli Hospital, Hebron, 00970, Palestine.
Echinococcus larval stage or a hydatid cyst, a parasitic disease that passes from animals to humans. Echinococcus granulosus and, less commonly, Echinococcus multilocularis species cause the disease. Intracranial echinococcosis is rare, with an incidence of approximately 1%-2%.
View Article and Find Full Text PDFPurpose: UGN-101, a reverse thermal mitomycin gel for upper tract instillation, recently became the first FDA approved treatment for upper tract urothelial carcinoma (UTUC). However, the durability of UGN-101 treatment has not been well described. Here we present long term outcomes from our multi-institutional cohort for patients who initially responded to treatment.
View Article and Find Full Text PDFComparative outcomes of ultrasound-guided radiofrequency ablation vs. microwave ablation for patients with T1N0M0 papillary thyroid carcinoma: a retrospective cohort study.
Eur Radiol
January 2025
Department of Ultrasound, First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China.
Objective: To compare the clinical outcomes between radiofrequency ablation (RFA) and microwave ablation (MWA) for the treatment of T1N0M0 papillary thyroid carcinoma (PTC) in a large cohort.
Materials And Methods: This retrospective study included 1111 patients with solitary T1N0M0 PTC treated with RFA (n = 894) or MWA (n = 215) by experienced physicians. A propensity score matching was used to compare disease progression, including lymph node metastases (LNM), recurrent tumors and persistent tumors, recurrence-free survival (RFS), volume reduction ratio (VRR), and complications between the RFA and MWA groups.
The effectiveness and safety of computed tomography-guided hook-wire localization for secondary video-assisted thoracoscopic surgery: a retrospective study.
J Thorac Dis
December 2024
Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background: Computed tomography (CT)-guided hook-wire localization is currently the most commonly used technique for preoperative localization of pulmonary nodules in clinical practice. With the increasing incidence of multiple primary lung cancers and the increasing occurrence of second primary lung cancers or local recurrences after lung cancer surgery, some patients need to undergo an ipsilateral or contralateral second pulmonary resection. In order to reduce the surgical difficulty of the second operation and accurately guide the surgical resection, preoperative localization of some nodules is necessary.
View Article and Find Full Text PDFUnusual recurrence in advanced ovarian cancer after interval cytoreductive surgery and HIPEC.
BMJ Case Rep
January 2025
Surgical Oncology, Aster Hospitals Inc, Bangalore, Karnataka, India.
Ovarian cancer is the second most fatal gynaecological malignancy. The relapses after treatment of ovarian cancer usually occur within 2 years after completion of the first-line therapy. Recurrent ovarian cancer commonly presents as peritoneal surface deposits in the abdomen with or without ascites.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!